| Literature DB >> 19112808 |
Holly R Mason1, Jil K Swanson, Jonhan Ho, Timothy J Patton.
Abstract
Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004. The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19112808
Source DB: PubMed Journal: J Drugs Dermatol ISSN： 1545-9616 Impact factor: 2.114